The vast majority of cancer cells have defective checkpoints that permit the cell cycle to progress in the presence of double-strand DNA breaks (DSBs) caused by ionizing radiation (IR) and radiomimetic drugs. ATR (ataxia telangiectasia-mutated and Rad3-related) has recently been shown to be activated by DSBs, although the consequences of this activity are largely unknown. In this report, we use advanced gene targeting methods to generate biallelic hypomorphic ATR mutations in human colorectal cancer cells and demonstrate that progression of the cancer cell cycle after IR treatment requires ATR. Cells with mutant ATR accumulated at a defined point at the beginning of the S phase after IR treatment and were unable to progress beyond that point, whereas cells at later stages of the S phase during the time of irradiation progressed and completed DNA replication. The prolonged arrest of ATR mutant cancer cells did not involve the ataxia telangiectasia mutated-dependent S-phase checkpoint, but rather closely resembled a previously characterized form of cell cycle arrest termed S-phase stasis. As ATR strongly contributed to clonogenic survival after IR treatment, these data suggest that blocking ATR activity might be a useful strategy for inducing S-phase stasis and promoting the radiosensitization of checkpointdeficient cancer cells.
Introduction
The phosphoinositide-3-kinase-like protein kinases ataxia telangiectasia-mutated (ATM) and ataxia telangiectasiamutated and Rad3-related (ATR) signal in response to chromosomal DNA damage by phosphorylating downstream substrates, including the checkpoint kinases Chk2 and Chk1, respectively (Abraham, 2001) . These multitiered signaling pathways coordinate cell cycle arrest at the G 1 /S, intra-S and G 2 /M checkpoints, activate DNA repair and can trigger apoptosis (Zhou and Elledge, 2000; McGowan and Russell, 2004) . Defects in these pathways are among the most universal alterations found in human cancer cells and are thought to underlie the sensitivity of tumors to DNA-damaging therapy, including ionizing radiation (IR) (Kastan and Bartek, 2004) .
In cooperation with its binding partner ATR-interacting protein (ATRIP), ATR becomes activated in regions of replication protein A (RPA)-coated singlestranded DNA that accumulate when DNA replication forks stall (Cortez et al., 2001) . Studies in yeast (Cha and Kleckner, 2002) and Xenopus (Shechter et al., 2004) model systems have shown that ATR homologs function at active replicons to suppress DNA breaks and prevent fork stalling. Recent reports have demonstrated that ATR is activated at double-strand DNA break (DSB) sites, suggesting that ATR contributes to IR responses in human cells (Adams et al., 2006; Cuadrado et al., 2006; Jazayeri et al., 2006; Myers and Cortez, 2006) . These reports have shown that ATR colocalizes with phosphorylated Chk1 at sites of DSBs (Adams et al., 2006; Jazayeri et al., 2006) and that Chk1 phosphorylation after IR exposure is largely ATRdependent.
Although it is now clear that ATR is activated by DSBs, the consequences of ATR activation remain incompletely defined. Studies with conditional knockout mouse cells have revealed that ATR contributes to at least one IR-dependent checkpoint (Osborn et al., 2002) . An important downstream target of ATR, Chk1, has been shown to modulate the S-phase checkpoint triggered by IR. In addition, inhibition of ATR function has recently been shown to result in the activation of p38 stress-activated protein kinase (Jirmanova et al., 2005) , a cell cycle regulator. These diverse studies suggest that ATR might have multiple roles in the regulation of the cell cycle after IR treatment. As ATR is not mutated in the vast majority of human cancers, ATR function is likely to be conserved in checkpoint-defective cancer cells.
We sought to investigate the roles of ATR in the cancer cell cycle in response to the DSBs caused by IR treatment. Using recently developed gene-targeting techniques (Topaloglu et al., 2005) , we have introduced a hypomorphic ATR mutation into a human colorectal cancer cell line that harbors mutant p53 alleles and therefore has defective checkpoints. Unexpectedly, we found that in response to IR, checkpoint-deficient cancer cells with hypomorphic ATR alleles failed to progress beyond a critical point in the cell cycle. We demonstrate that this prolonged arrest is indistinguishable from a state previously termed S-phase stasis, in which prolonged arrest at the onset of S phase precludes cell cycle progression (Borel et al., 2002) . Our studies show that IR can induce S-phase stasis in the presence of limiting ATR and suggest that inhibition of ATR activity might be a useful strategy for radiosensitizing cancer cells.
Results

Generation of ATR-Seckel cancer cells by homologous recombination
The human colorectal cancer cell line DLD1 (also known as HCT15) exhibits robust growth characteristics and has been extensively characterized. This cell line was chosen as a model system for several reasons. Targeting in a human cell line allows for the comparison of targeted cells with isogenic wild-type control cells. Importantly, DLD1 cells have a defective G 1 /S checkpoint in response to IR owing to the biallelic mutation of the tumor suppressor gene p53 (O'Connor et al., 1997) . DLD1 also harbor an inactivating mutation on one CHK2 allele and exhibit loss of expression of the remaining allele (Falck et al., 2001a) . DLD1 have two copies of chromosome 3, facilitating the biallelic targeting of the ATR locus.
Genetic analysis of the ATR-dependent responses to DSBs has been hampered by the synthetic lethality of null mutants in both mice (Brown and Baltimore, 2000) and human cells (Cortez et al., 2001) . A recently described point mutation in the ATR gene has been shown to be a cause of Seckel syndrome (O'Driscoll et al., 2003) , an inherited disorder characterized by severe intrauterine growth retardation, proportionate dwarfism, microcephaly, and skeletal and brain abnormalities (Seckel, 1960) . Interestingly, unlike some other mutations in genes that modulate DNA damage signaling, the ATR-Seckel mutation does not appear to cause a predisposition to cancer .
We used recombinant adeno-associated virus (rAAV)-based gene targeting (Topaloglu et al., 2005) to knock-in the point mutation associated with ATR-Seckel syndrome into DLD1 cells. An rAAV delivered a targeting construct carrying the ATR-Seckel mutation A2101G (Figure 1a ). After one round of infection, selection and polymerase chain reaction (PCR) screening, clones in which the targeting construct had integrated into the ATR locus were identified and expanded. The amplification of the genomic ATR region outside the region of homology to the targeting construct and direct sequencing of these PCR products identified the heterozygous A/G at position 2101 after one round of targeting and confirmed a homozygous G after two rounds of targeting (Figure 1b) . These knock-in cell lines were designated DLD-ATR-HET and DLD-ATRSeckel, respectively.
Knock-in cells recapitulate Seckel syndrome phenotypes
The ATR-Seckel mutation causes aberrant splicing of ATR that leads to a near-complete lack of full-length ATR transcripts, thereby causing a hypomorphic phenotype (O'Driscoll et al., 2003) . Analysis of ATR transcripts by reverse transcription (RT)-PCR showed the appearance of a major amplified product with a size (295 bp) that was consistent with skipping of exon 9 in DLD-ATR-HET and DLD-ATR-Seckel cells (Figure 1c Immunoblotting revealed a decreased amount of ATR protein in DLD-ATR-HET cells, whereas ATR protein was undetectable in DLD-ATR-Seckel cells (Figure 1d) .
A significant phenotype previously observed in cells from ATR-Seckel patients, and directly attributed to ATR deficiency, is a marked sensitivity to ultraviolet radiation (UV) (O'Driscoll et al., 2003; Alderton et al., 2004) . As measured by clonogenic survival, the DLD-ATR-Seckel cells were approximately 10-fold more sensitive to UV than wild-type DLD1 over a range of doses (Figure 2a ), thereby providing functional confirmation of ATR deficiency in this engineered cell line.
ATR deficiency causes radiosensitivity and reduced IR-dependent phosphorylation of Chk1
We used this isogenic cancer cell system for rigorous analysis of the roles of ATR in the responses of cancer cells to IR. Clonogenic survival was measured after exposing cell cultures to varying doses of IR. DLD-ATR-Seckel cells were nearly 10-fold more sensitive to IR at doses over 2 Gy (Figure 2b ). This is consistent with previous studies that have detected radiosensitivity in cancer cells following forced overexpression of a kinasedead ATR mutant (Cliby et al., 1998) .
We next examined ATR-mediated signaling in that dose range. In response to DNA damage, Chk1 is phosphorylated on two highly conserved serine residues, serine 317 and serine 345 (Zhao and Piwnica-Worms, 2001 ). Chk1 phosphorylation was analysed by probing whole-cell lysates with phosphoserine-specific antibodies. In DLD1 cells with wild-type ATR, Chk1 was phosphorylated to only a small extent at both serines 317 and 345 after exposure to 2 Gy IR, whereas a robust phosphoserine signal was detected at all doses higher than 6 Gy ( Figure 2c ). Phosphorylation of Chk1 at both sites was markedly reduced in DLD-ATR-Seckel cells, even at the higher IR doses tested. The dose range at which the DLD-ATR-Seckel cells were more radiosensitive was thus the same range at which Chk1 was optimally phosphorylated by ATR. IR doses above 6 Gy did not significantly increase the extent of Chk1 phosphorylation, nor were the ATR-dependent differences in IR sensitivity more pronounced at these higher IR doses.
Conditional loss of ATR in mouse cells has been shown to cause loss of the IR-dependent G 2 /M checkpoint (Brown and Baltimore, 2003) . We employed a nocodazole trap to capture and to quantify cells that entered mitosis. During an 18-h period following IR exposure, a substantial proportion of DLD-ATR-Seckel cells, but few parental DLD1 cells entered mitosis (Figure 2d ). As G 2 arrest is unstable in these p53 mutant cells (Bunz et al., 1998) , all cells entered mitosis at later times (data not shown).
ATR is required for cancer cell cycle progression in the presence of DSBs Asynchronous cells were exposed to IR and changes in their distribution throughout the cell cycle were measured by flow cytometry (Figure 3 ). The addition of the microtubule inhibitor nocodazole to all cultures blocked cells in mitosis and thus prevented nascent cells from re-entering the 2N population. Under these conditions, the size of the 2N population was inversely dependent on the entry of cells into the S phase.
Unirradiated cells progressed through the cell cycle efficiently regardless of genotype, and by 15 h, virtually all cells had accumulated in a single nocodazole-arrested peak with 4N DNA content (Figure 3 ). IR treatment notably altered the dynamics of cell cycle progression in both cell lines. Although the irradiated DLD1 cells progressed from 2N into the S phase as a nearly synchronous population, the S-phase fraction of the unirradiated cells remained fairly constant over the course of the experiment. This synchronous population did not form in the irradiated DLD-ATR-Seckel cell culture, suggesting that progress through the early stages of the S phase after IR was an active process, dependent on ATR activation.
In wild-type DLD1 cells, exposure to 12 Gy IR caused the mass movement of cells into S phase by 6 h. Between 9 and 15 h after IR, virtually all of the cells in the DLD1 culture had entered and moved through the S phase and had accumulated in a single peak with 4N DNA content. Like the majority of cancer cells (Kastan and Bartek, 2004) , wild-type DLD1 exhibited a defective G 1 /S checkpoint and nearly all cells progressed into the S phase; very few DLD1 cells remained arrested at 2N. In contrast, progress into the S phase after IR was markedly decreased in DLD-ATR-Seckel cells. By the end of the 15 h time course, nearly 50% of the cells in the DLD-ATR-Seckel population had failed to achieve 4N DNA content.
Failure of ATR-deficient cells to resume cycling following synchronization at G 1 /S Given the failure of 2N cells to progress in the cell cycle following irradiation of the DLD-ATR-Seckel population, we sought to further examine the progression of cells from G 1 into the S phase. We trapped cells at all stages of the S phase by incubation with thymidine and also synchronized cells at the G 1 /S transition by sequential treatment with thymidine and aphidicolin, a DNA polymerase inhibitor (Figure 4) .
A 16-h incubation in the presence of thymidine halted DNA replication and resulted in the distribution of cells throughout the S phase in both cell lines. Following release from the thymidine block, the DLD-ATR-Seckel cells transitioned from 2N to 4N more slowly than control cells. Nonetheless, a significant proportion of cells completed DNA replication by 9 h. To synchronize cells at the transition between G 1 and S phases, we employed a double thymidine/aphidicolin block, in which the thymidine treatment was followed by an 8-h recovery period and 16 h treatment with aphidicolin. Cells of both genotypes arrested at G 1 /S in a sharp peak. Upon release from the double block, only cells with wild-type ATR were able to progress efficiently through the S phase. The majority of DLD-ATR-Seckel cells remained in the 2N peak, whereas only a small fraction wild-type DLD1 failed to progress. These results showed that cells arrested within the S phase could subsequently progress through the cell cycle regardless of genotype, whereas progression of cells arrested at the onset of S required ATR. 
IR-dependent S-phase checkpoint is intact in ATR-deficient cells
Exposure to IR causes a transient reduction of the rate of DNA synthesis known as the S-phase checkpoint. Cells with a defective S-phase checkpoint exhibit radioresistant DNA synthesis (RDS), which was first recognized in cells from ataxia telangiectasia patients (Painter and Young, 1980) . Accordingly, the canonical cause of the RDS phenotype is loss of ATM function (Kastan and Lim, 2000; Abraham, 2001) . We sought to determine whether ATR, as a downstream component of the ATM response, might play a role at this checkpoint and contribute to the cell cycle defects observed. The S-phase progression is regulated by the activation of Cdk2/cyclin E by the Cdc25A phosphatase (Donzelli and Draetta, 2003) . When the S-phase checkpoint is triggered, Cdc25A itself becomes phosphorylated and is thereby targeted for proteosome-dependent degradation (Bernardi et al., 2000; Mailand et al., 2000) . Cdc25A is phosphorylated by Chk1 (Sanchez et al., 1997) and this highly conserved signaling event has been shown to affect Cdc25A protein turnover after IR as well as during unperturbed S phase (Sorensen et al., 2003) .
We measured active DNA synthesis by the incorporation of 3 H-methyl-labeled thymidine, which is exclusively incorporated into newly synthesized DNA. One hour after IR treatment, both cell lines exhibited a proportionally similar reduction in 3 H-thymidine uptake (Figure 5a ). ATR deficiency was therefore not observed to increase further the RDS phenotype in these cells.
Chk1 phosphorylation after IR was markedly lower in the DLD-ATR-Seckel cells over a time course (Figure 5b ). In both DLD1 and DLD-ATR-Seckel cells, Cdc25A degradation was observed at 1 h. By 6 h Cdc25A protein reappeared in both cell lines. Thus, Cdc25A levels responded normally to IR, despite marked differences in Chk1 phosphorylation on serine 317, and to a greater extent, on serine 345. An assessment of Cdk2-complex activity also suggested that the S-phase checkpoint was intact. In vitro assays of cyclin A-, cyclin E-and Cdk2-associated kinases all showed a marked reduction in histone H1 phosphorylation 1 h after IR exposure, with activity recovered by 9 h (Figure 5c ).
To examine the population of cells in the S phase in more detail, we labeled cells undergoing active DNA synthesis with the nucleotide analog bromodeoxyuridine (BrdU). DLD-ATR-Seckel cells that had been treated with UV 30 min before labeling showed a markedly reduced BrdU-positive fraction as compared with wildtype DLD1 (Figure 5d ). This suggests that ATR is essential for S-phase recovery following exposure to UV, consistent with earlier studies (Osborn et al., 2002; Alderton et al., 2004) . IR treatment, however, caused decreased BrdU uptake in both cell lines, consistent with the observed decrease in thymidine uptake (Figure 5a) .
To follow the progression of cells in S phase at the time of IR treatment, we performed a pulse-chase experiment (Figure 5e ). After BrdU labeling, cells were incubated in fresh medium without BrdU and then irradiated. Cells joined the 4N population to a similar extent regardless of genotype. This suggests that the defects in cell cycle progression (Figure 3) were the result of defects in the S-phase entry, rather than progression through the S phase.
Discussion
In this report, we investigate the role of ATR in checkpoint-deficient cancer cells exposed to IR. Unexpectedly, we found that ATR promoted the progression of cancer cells into the S phase in the presence of DSBs, whereas cells with limiting ATR accumulated at the onset of the S phase. This form of arrest is indistinguishable from a previously described phenomenon in which cells fail to progress in the cell cycle after prolonged arrest at the beginning of the S phase (Borel et al., 2002) . The molecular basis for this phenomenon, termed S-phase stasis by Margolis and co-workers, has up to now been obscure. We show that ATR-deficient cells displayed a high rate of S-phase stasis following inhibition of DNA synthesis by aphidicolin. Importantly, an arrest pattern identical to S-phase stasis could be induced by IR in the context of ATR deficiency. Thus, we show that progression past the onset of the S phase in the presence of DSBs is an active process that depends on ATR activity.
Interestingly, we found that cells in the midst of the S phase at the time of irradiation were able to progress in the presence of DSBs (Figure 5e ), whereas the cells entering the S phase from G 1 could not progress further. Although the localization and activation of ATR at DSB sites has been detected in cyclin A-positive cells in S-and G 2 -phase cells (Jazayeri et al., 2006) , there is also evidence indicating that ATR might be activated before the onset of DNA synthesis (Adams et al., 2006) .
It might seem counterintuitive for a checkpoint regulator also to stimulate cell cycle progression. What could be the purpose of such an activity? The answer might lie in the DSBs that occur, transiently and in low numbers, during normal DNA replication (SalehGohari et al., 2005) . As a sensor of the RPA-coated regions of single-stranded DNA that accumulate when replication forks slow or stall, ATR directly monitors the progress of DNA replication. It has recently been shown that inhibition of Chk1 increases the frequency of DNA breaks during replication (Syljuasen et al., 2005) . Collectively, these data suggest a feedback loop, in which the rate of replication-associated DNA breakage is directly controlled by the activation of Chk1 by ATR, which is itself activated by such breaks. It is tempting to speculate that, during the early stages of normal DNA replication, ATR might respond to DSBs arising from stalled forks by initiating new replicons, thereby promoting S-phase progression. Such an activity might be less important later in the S phase, when a majority of active replicons have already fired. Additional studies of replication fork dynamics in ATR-deficient human cells are necessary to test this hypothesis.
Despite a marked lack of Chk1 phosphorylation in response to IR, the ATR mutant cells characterized in this study did not show any significant differences in the activation of the S-phase checkpoint. It may be possible that the small amount of ATR protein produced by the hypomorphic ATR-Seckel alleles, and the relatively low amount of Chk1 phosphorylation observed, was sufficient to trigger normal degradation of Cdc25A. Alternatively, there may be a downstream effector of ATM other than Chk1 that functions in this capacity. The identity of the primary downstream effector of ATM with regard to the S-phase checkpoint remains an interesting question. There has been controversy over whether Chk2 plays a primary role. The DLD1 cells used in this study are known to harbor a CHK2 mutation and exhibit deficient Chk2 expression. Although we and others have shown that these cells exhibit a clear S-phase checkpoint response, this response could be enhanced by overexpression of Chk2 (Falck et al., 2001b) . Analysis of Chk2-deficient mouse cells revealed largely intact S-phase responses (Hirao et al., 2002) . In any case, the impact of the S-phase checkpoint on cancer cell survival is unknown. In fission yeast, abrogation of the S-phase checkpoint pathways has little impact on resistance to DNA-damaging agents (Kumar and Huberman, 2004) .
Radiotherapy is a widely used and in many cases a highly effective form of anticancer treatment. The genetic determinants that affect the sensitivity of normal and cancer cells to therapy are poorly understood. Studies using gene-targeted cell lines should prove useful in the evaluation of genes that potentially alter therapeutic responses. In particular, it will be important to examine in detail the impact of P53 status on the effects that we have reported in this paper. Finally, in vivo studies using mouse tumor models will be critical to determining whether inhibition of ATR provides a therapeutic effect that is cancer cell-specific. The radiosensitivity exhibited by the ATR mutant cancer cells generated in this study is encouraging, and suggests that pharmacologically targeting ATR, and thereby promoting S-phase stasis, might be effective strategies to radiosensitize tumors in a clinical setting.
Materials and methods
Gene targeting
The human colon cancer cell line DLD1 and derivatives were cultured in McCoy's 5A medium supplemented with 10% fetal calf serum (Hyclone, Logan, UT, USA) and penicillin/ streptomycin (Invitrogen, Carlsbad, CA, USA). An rAAV was used for gene targeting (Topaloglu et al., 2005) . The A2101G mutation found in ATR-Seckel patients was incorporated into a cloned 2.5 kb region of the ATR locus, including exons 9 and 10, by site-directed mutagenesis. A targeting construct was configured by inserting a neomycin transferase expression cassette (neo), flanked by LoxP sites, into intron 9. This targeting construct was then subcloned into an rAAV shuttle vector and infectious virus was produced using an AAV helper-free system (Stratagene, La Jolla, CA, USA). Targeted clones were obtained as described previously (Topaloglu et al., 2005) .
Analysis of ATR transcripts
RNA was extracted and purified with spin columns (Qiagen, Valencia, CA, USA). RT-PCR was performed using a Superscript single tube RT-PCR kit (Invitrogen) with primers specific to ATR exon 8 (5 0 -TGTGGTATGCTCTCACTTCC-3 0 ) and exon 10 (5 0 -CATTCATGTTGAGAAGTGGC-3 0 ).
Irradiation
Cells were grown as subconfluent monolayers and exposed to IR from a 137
Cs source that delivered a measured dose of 0.8 Gy/min. UV was delivered at a rate of 1 Jm À2 /s. Where indicated, nocodazole was added to the cell culture medium at a final concentration of 0.2 mg/ml immediately following irradiation.
Cell cycle analysis
Cells were collected by incubation in trypsin/ethylenediaminetetraacetic acid, pelleted by centrifugation and fixed in phosphate-buffered saline (PBS) containing 3.7% formaldehyde, 0.5% Nonidet P-40 and 10 mg/ml Hoechst 33258. A total of 10 000 cells were analysed per sample on a flow cytometer (BD Biosciences, Rockville, MD, USA). Mitotic indices were determined by visual scoring of at least 300 nuclei under fluorescence. For BrdU staining, cells were labeled with 10 mg/ ml BrdU for 30 min. Cells were harvested and pelleted, washed in PBS containing 1% bovine serum albumin and re-suspended in PBS on ice. Cells were fixed in chilled 70% ethanol. Before staining, cells were denatured with 2 M HCl, neutralized with 0.1 M NaBO 4 and stained with fluorescein isothiocyanateconjugated anti-BrdU antibody (BD Biosciences) and propidium iodide (Molecular Probes, Eugene, OR, USA). Thymidine was used at a concentration of 2.5 mM and aphidicolin was used at a concentration of 2 mg/ml. Both reagents were purchased from Sigma (St Louis, MO, USA).
DNA synthesis
Cells were labeled with 10 nCi/ml [ 14 C-methyl]thymidine for 24 h, washed and then grown in fresh medium for an additional 24 h. At the indicated time points, 2.5 mCi/ml [ 3 Hmethyl]thymidine was added to each well and incubated for 15 min. Labeled cells were washed with PBS, collected with trypsin and pelleted by centrifugation. Cells were washed with PBS, and fixed in 70% methanol overnight at 41C. Fixed cells were filtered through glass fiber filters, which were washed in 95% methanol and dried. Levels of 3 H and 14 C incorporation were measured by liquid scintillation. DNA synthesis activity was measured as the 3 H channel reading normalized to the 14 C channel reading and corrected for channel crossover. Radiochemicals were purchased from Amersham (Buckinghamshire, UK).
Immunoblotting Whole-cell lysates were denatured, sonicated and fractionated on NuPAGE gels (Invitrogen). Proteins were transferred to polyvinylidene difluoride membranes, which were then incubated with antibodies directed against ATR, Chk1, Cdc25A, Cdk2, cyclin A, cyclin E, a tubulin, (Santa Cruz Biotech., Santa Cruz, CA, USA), phospho-Chk1 (ser317) and phosphoChk1 (ser345) (Cell Signaling Technologies, Beverly, MA, USA) under conditions recommended by the manufacturers. Blots were developed using enhanced chemiluminescence (Amersham).
In vitro kinase assays Cell lysates were prepared and cyclin-dependent kinase assays were performed as in Bunz et al. (1998) , using Histone H1 (Upstate Biotechnology, Lake Placid, NY, USA) as a substrate.
